Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
Tirzepatide Phase 1 Trial
A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.